drugset / Trial / NCT01106872

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

NCT01106872

Phase 1 Completed 47 enrolled Mohammed M Milhem Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.

Timeline

Start
2010-09
Primary completion
2017-07
Completion
2017-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody
Subject Docetaxel Small molecule
Subject Gemcitabine Small molecule
Subject Valproic Acid Small molecule

Indications